Form 4: GoodRx Holdings to Repurchase $105.1 Million in Class A Common Stock from Francisco Partners

GoodRx Holdings will repurchase 14,622,366 shares of Class A Common Stock from Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P. for approximately $105.1 million.

Summary

• GoodRx Holdings, Inc. has agreed to repurchase an aggregate of 14,622,366 shares of its Class A Common Stock from Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P.
• The total purchase price for the shares is $105,134,811.54, implying a price of $7.19 per share.
• The transaction involves the conversion of 14,622,366 shares of Class B Common Stock into Class A Common Stock on a one-for-one basis.
• The repurchase is expected to close on March 11, 2024.
• Following the transaction, Francisco Partners IV, L.P. will beneficially own 9,740,254 Class A shares and Francisco Partners IV-A, L.P. will beneficially own 4,882,112 Class A shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The repurchase could be seen as a positive sign of the company's financial health and confidence, but it also reduces their cash reserves.

Positives

• The share repurchase may be viewed positively as it reduces the number of outstanding shares, potentially increasing earnings per share.
• The repurchase demonstrates GoodRx's confidence in its future prospects and financial position.

Risks

• The document does not explicitly state any risks, but the repurchase reduces GoodRx's cash reserves.
• The reliance on Francisco Partners' continued holding of a significant portion of shares could pose a risk if they decide to sell a large stake in the future.

Future Outlook

The document indicates the repurchase is expected to close on March 11, 2024, but does not provide further forward-looking statements regarding GoodRx's future performance or strategy.

Industry Context

Share repurchases are a common method for companies to return capital to shareholders, especially when they believe their stock is undervalued. This move could be seen as a way for GoodRx to consolidate its stock and potentially boost its share price.

Comparison to Industry Standards

• Share repurchases are a common capital allocation strategy among publicly traded companies, particularly in the tech and healthcare sectors.
• Companies like Teva Pharmaceutical Industries Ltd. and CVS Health Corporation have also engaged in share repurchase programs to enhance shareholder value.
• The size of the repurchase relative to GoodRx's market capitalization would be a key factor in assessing its impact compared to industry peers.

Related Party Transactions

• The share repurchase from Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P. constitutes a related party transaction, as Francisco Partners is a significant shareholder (10% Owner).

Stakeholder Impact

• Shareholders may see a slight increase in EPS due to the reduced share count.
• The company's cash reserves will be reduced by the amount of the repurchase.

Next Steps

• The repurchase is expected to close on March 11, 2024.

Key Dates